Introduction
============

Atherosclerosis is a progressive inflammatory process and is the major cause of death in patients with type 2 diabetes mellitus (T2DM).[@b1-vhrm-14-225],[@b2-vhrm-14-225] In particular, endothelial cells, monocytes and platelets play important roles in the development of atherosclerosis.[@b2-vhrm-14-225] Low-density lipoprotein (LDL) could be used to predict the onset and death of Japanese atherosclerosis-associated diseases.[@b3-vhrm-14-225] In addition, a large-scale clinical trial in Japan in which patients were examined for hypercholesterolemia and subsequently intervened in a lifestyle improvement program has reported that coronary diseases can be significantly controlled.[@b4-vhrm-14-225],[@b5-vhrm-14-225]

The underlying pathology of arteriosclerosis obliterans (ASO) is basically atherosclerosis with often observed complete thrombi occlusions.[@b6-vhrm-14-225] The ASO-related biomarkers such as C-reactive protein (CRP), interleukin (IL)-6, soluble E-selectin (sE-selectin), soluble vascular cell adhesion molecule (sVCAM)-1 and plasminogen activator inhibitor (PAI)-1 are markedly elevated in patients with T2DM.[@b7-vhrm-14-225]--[@b11-vhrm-14-225] In addition to these biomarkers, platelet-derived microparticle (PDMP) is significant in atherosclerosis in T2DM patients, because these patients typically display hypercoagulability and platelet hyperaggregability with increased levels of platelet activation markers.[@b8-vhrm-14-225],[@b12-vhrm-14-225]--[@b14-vhrm-14-225] The PDMPs are generated by platelet activation and play roles in normal hemostatic responses to vascular injury.[@b15-vhrm-14-225]--[@b18-vhrm-14-225] In addition, it is thought that PDMPs contribute to thrombin generation and thrombus formation by generating tissue factor.[@b14-vhrm-14-225],[@b19-vhrm-14-225],[@b20-vhrm-14-225] Therefore, PDMPs may ultimately cause vascular complications in T2DM with the participation of the blood coagulation system.

Another important biomarker in T2DM-related atherosclerosis is adiponectin.[@b21-vhrm-14-225]--[@b23-vhrm-14-225] Adiponectin is an adipokine with anti-inflammatory, antiatherogenic and insulin-sensitizing properties.[@b23-vhrm-14-225] Adiponectin possibly suppresses the attachment of monocytes to endothelial cells,[@b24-vhrm-14-225] and stimulates nitric oxide production in vascular endothelial cells, which ameliorates endothelial function.[@b21-vhrm-14-225],[@b24-vhrm-14-225] In addition, adiponectin inhibits tissue factor expression and enhances tissue factor pathway inhibitor expression in human endothelial cells.[@b25-vhrm-14-225] These observations suggest that hypoadiponectinemia may be associated with an increased incidence of vascular disease in T2DM.

Therefore, it is thought that the novel therapeutic strategy of ASO-related biomarkers for lipid abnormality is important for atherosclerosis in T2DM patients. In particular, the countermeasure for platelet activation and endothelial dysfunction is necessary. We previously reported that the combination therapy of pitavastatin and eicosapentaenoic acid (EPA) may be beneficial for the prevention of vascular complication in hyperlipidemic patients with T2DM.[@b26-vhrm-14-225] Pitavastatin has various pleiotropic effects, resulting in the improvement of endothelial function and preventing the progression of aortic atherosclerosis.[@b27-vhrm-14-225],[@b28-vhrm-14-225]

Studies have reported other effects of EPA on serum lipids, including a unique preventive effect against atherosclerotic disease and coronary events.[@b29-vhrm-14-225]--[@b31-vhrm-14-225] However, the influence of other antiplatelet drugs besides EPA on pitavastatin treatment for ASO in T2DM patients is poorly understood. In our present study, we compared the effect of sarpogrelate[@b32-vhrm-14-225],[@b33-vhrm-14-225] or EPA on pitavastatin treatment for ASO in T2DM, focusing on the antiatherosclerotic properties of these combination therapies (SARpogrelate-EPA-PITavastatin-ASO \[SAREPITASO\] study). All three of these drugs have a common feature that raises the level of adiponectin.[@b26-vhrm-14-225],[@b34-vhrm-14-225]--[@b36-vhrm-14-225]

Patients and methods
====================

Study design
------------

The SAREPITASO study is a randomized, non-blinded, parallel-group study. We enrolled patients who satisfied all inclusion criteria. All study participants provided signed informed consent, and this study was approved by the ethics committee of Kansai Medical University, Hirakata, Osaka, Japan (no. 110614).

Study population
----------------

The study group included 84 T2DM patients and 50 non-diabetic controls. Between August 2012 and March 2016, we selected participants from T2DM patients admitted to our hospital for treatment. Entry criteria required that participants had no history of inflammatory, coronary artery or cerebrovascular disease, or no clinically detectable renal (serum creatinine ≥2.0 mg/dL), hepatic (elevated serum transaminase levels), infectious (fever or elevated white blood cell count) or malignant disease (based on ultrasound or computed tomography examination) within the 3 months before enrollment. Other antithrombotic agents were prohibited to avoid potential influence of data interpretation. The concomitant use of these drugs was fixed for a certain period before study entry.

Study protocol
--------------

Pitavastatin of 2 mg with either EPA 1,800 mg or sarpogrelate 300 mg was administered daily for 12 months ([Figure 1](#f1-vhrm-14-225){ref-type="fig"}). No other pharmacologic regimen changes occurred during treatment in any of the patients. Clinical and biochemical data obtained before and after pitavastatin with either EPA (PE group) or sarpogrelate (PS group) administration were compared. There were 19 patients using an angiotensin II receptor blocker (ARB) and 14 patients using a Ca antagonist for hypertension in T2DM. Of these patients, 52 were treated with sulfonylureas, 56 with α-glucosidase inhibitors, 47 with DPP4 inhibitor and 41 with insulin. The doses of drugs were not adjusted during the study. Hyperlipidemia was defined according to the Guidelines for Diagnosis and Treatment of Hyperlipidemias in Adults published by the Japan Atherosclerosis Society.[@b37-vhrm-14-225] The American Diabetes Association criteria were used to define T2DM.[@b38-vhrm-14-225] [Table 1](#t1-vhrm-14-225){ref-type="table"} shows the clinical characteristics of the T2DM patients and the control subjects.

Endpoints
---------

The primary endpoint was improvement of ankle brachial pressure index (ABI) within 12 months. The secondary endpoints were changes in levels of 1) body mass index (BMI); 2) total cholesterol, high-density lipoprotein cholesterol and LDL cholesterol; 3) glycated hemoglobin (HbA1c); 4) CRP, IL-6 and monocyte-chemoattractant protein (MCP)-1; 5) sE-selectin, sVCAM-1 and PAI-1; 6) PDMP and 7) adiponectin.

Assessment of PDMP
------------------

The PDMP levels were measured twice and the mean values were recorded. Furthermore, some basic studies were carried out before this assessment using clinical specimens. An enzyme-linked immunosorbent assay (ELISA) kit was used for PDMP measurements (JIMRO Co. Ltd., Tokyo, Japan).[@b16-vhrm-14-225]

Measurements of cytokine, soluble factors and adiponectin
---------------------------------------------------------

Fasting blood samples from patients and controls were collected into tubes either with or without sodium citrate and allowed to clot at room temperature for a minimum of 1 hour. Citrated plasma or serum samples were isolated by centrifugation at 1,000×*g* for 20 minutes at 4°C and stored at −30°C until analysis. Plasma concentrations of IL-6, MCP-1, sE-selectin, sVCAM-1 and PAI-1 were measured using monoclonal antibody-based ELISA kits (Thermo Fisher Scientific, Waltham, MA, USA), and plasma adiponectin was measured with adiponectin ELISA kits (Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan). The recombinant products and standard solutions provided with each kit were used as positive controls in each assay, and all procedures were performed according to the manufacturers' instructions.

Statistical analysis
--------------------

Data were expressed as mean±SD and were analyzed using multivariate regression analysis, as appropriate. Between-group comparisons were performed using the Newman--Keuls test and the Scheffe's test. The correlation between uric acid concentration and continuous variables was assessed using multivariate linear regression analysis. The significance of differences among variables was determined by analysis of variance. *P*-values \<0.05 were considered statistically significant. All analyses were performed using the StatFlex program (version 6).

Results
=======

Omitted patients
----------------

There were no cardiovascular events, cases of cerebral infarction or cases of liver dysfunction. Five T2DM patients showed abnormal laboratory data (renal failure and infections) and three T2DM patients changed hospital. Therefore, we collected and analyzed data from 50 nondiabetic and 76 T2DM patients.

Clinical characteristics of T2DM patients
-----------------------------------------

Age, BMI, fasting blood glucose and HbA1c were higher in T2DM patients than in nondiabetic controls ([Table 1](#t1-vhrm-14-225){ref-type="table"}). However, ABI in T2DM patients was significantly lower than in nondiabetic controls. The values of total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol were similar in both groups before treatment ([Table 1](#t1-vhrm-14-225){ref-type="table"}).

Univariate and multivariate regression analyses
-----------------------------------------------

We investigated the associations between 16 variables and ABI concentration in T2DM patients ([Table 2](#t2-vhrm-14-225){ref-type="table"}). Univariate analysis showed that BMI, HbA1c, LDL, CRP, MCP-1, sE-selectin, sVCAM-1, PDMP, PAI-1 and adiponectin were factors significantly associated with ABI, whereas HbA1c, CRP, PDMP and PAI-1 were significantly correlated with ABI in multivariate analysis.

Comparison of changes in all markers of PS or PE groups after treatment
-----------------------------------------------------------------------

There were no significant differences in the clinical characteristics between the PS and PE groups before treatment ([Table 3](#t3-vhrm-14-225){ref-type="table"}). The levels of ABI, BMI, HbA1c and MCP-1 improved significantly after treatment in the PE group, although the PS group did not exhibit a significant change ([Figure 2](#f2-vhrm-14-225){ref-type="fig"}). The sE-selectin, sVCAM-1, PDMP and PAI-1 levels decreased significantly in the PE group after treatment, although the PS group did not exhibit significant changes ([Figure 3](#f3-vhrm-14-225){ref-type="fig"}). However, both groups displayed a significant increase in adiponectin levels after treatment, whereas the PE group exhibited greater significant changes ([Figure 3](#f3-vhrm-14-225){ref-type="fig"}).

Discussion
==========

Various factors are involved in diabetic vascular changes, one of which is platelet activation.[@b8-vhrm-14-225],[@b12-vhrm-14-225],[@b39-vhrm-14-225],[@b40-vhrm-14-225] Some platelet activation markers are elevated in patients with T2DM.[@b8-vhrm-14-225],[@b13-vhrm-14-225] The marker PDMP, which is derived from activated platelets, plays an important role in the process of coagulation, so that an increase of PDMP causes hypercoagulability.[@b18-vhrm-14-225] We previously reported that PDMPs were significantly increased in diabetic patients with high LDL levels compared with similar patients who had low LDL levels.[@b13-vhrm-14-225] Because PDMP enhanced the expression of adhesion molecules on monocytes and endothelial cells,[@b41-vhrm-14-225] it seems possible that PDMP may participate in the development or progression of atherosclerosis in patients with diabetes. The potential incapability of intensive antiplatelet drugs (cilostazol and ticlopidine) was previously reported.[@b42-vhrm-14-225],[@b43-vhrm-14-225] In addition, these drugs can inhibit the elevation of PDMP.[@b44-vhrm-14-225],[@b45-vhrm-14-225] However, the use of these drugs for primary prevention of atherothrombosis is problematic. For this reason, we evaluated EPA and sarpogrelate. We classified patients with diabetes into two groups according to combination therapy of either PE or PS. Interestingly, T2DM patients with PE exhibited a significant decrease of PDMP after treatment. These results correspond with previous reports on the microvascular complications of diabetes.[@b26-vhrm-14-225],[@b35-vhrm-14-225]

In patients with T2DM, a significant decrease in plasma adiponectin which prevents vascular complications has been found.[@b21-vhrm-14-225],[@b24-vhrm-14-225],[@b46-vhrm-14-225] In particular, we evaluated the efficacy of PS and PE therapy for hypoadiponectinemia and found that not only PE but also PS improves hypoadiponectinemia in T2DM. In addition, PE exhibited a better effect for adiponectin compared with PS. This result suggests that PE may exert its antiatherosclerotic effect via modification of adiponectin levels, thus contributing to the adiponectin-dependent PDMP-reducing action. Although the exact mechanism by which PE treatment leads to an increase in circulating adiponectin levels remains unclear, we previously reported about the role of the peroxisome proliferator-activated receptor gamma which can be activated by EPA.[@b36-vhrm-14-225],[@b47-vhrm-14-225]

Hypoadiponectinemia is associated with endothelial dysfunction[@b21-vhrm-14-225] and appears to cause platelet activation, since the levels of nitric oxide, which regulates platelet activation, are decreased in patients with hypoadiponectinemia. It has been reported that adiponectin stimulates the production of nitric oxide in vascular endothelial cells,[@b24-vhrm-14-225],[@b48-vhrm-14-225] resulting in platelet activation at low concentrations of nitric oxide. Thus, the increase of adiponectin by EPA may exert a platelet-inhibitory effect via nitric oxide. Our results suggest that EPA possesses multifunctional antithrombotic properties, and that its action is dependent on adiponectin. In particular, the significant reduction of ABI in the PE group might be important, because ABI has diagnostic significance for peripheral artery disease (PAD); the exacerbation of PAD is related to fatty acid and the abnormality of fatty acid is a death risk factor of events of the lower limbs.[@b49-vhrm-14-225],[@b50-vhrm-14-225] Furthermore, statin can control the outcome of lower limbs in PAD.[@b51-vhrm-14-225] Therefore, PE treatment is considered a useful strategy for the progression of vascular events in patients with T2DM.

Conclusion
==========

PE could increase ABI and circulating adiponectin levels in T2DM. In addition, PE could improve PDMP and endothelial activation markers such as sVCAM-1, sE-selectin and PAI-1 in T2DM. Therefore, PE may offer promise as a primary preventive therapy for atherothrombosis in T2DM, even though we were unable to recognize any specific clinical characteristics or occurrence of microvascular complications in this group of patients.
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![Schema of study protocol.\
**Abbreviations:** ABI, ankle branchial pressure index; BT, blood test; EPA, eicosapentaenoic acid; IC, informed consent; M, months; ST, special test.](vhrm-14-225Fig1){#f1-vhrm-14-225}

![Changes in ABI, BMI, HbA1c, IL-6 and MCP-1 in response to treatment with PS or PE in T2DM patients.\
**Notes:** Bars show the mean±SD. 0: before; M: months (after). *P*-values are for comparison with each baseline parameter (0 vs 6 and 12 months). ANOVA (PS vs PE).\
**Abbreviations:** ABI, ankle brachial pressure index; ANOVA, analysis of variance; BMI, body mass index; HbA1c, hemoglobin A1c; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; NS, nonsignificant; PE, pitavastatin with eicosapentaenoic acid; PS, pitavastatin with sarpogrelate; T2DM, type 2 diabetes mellitus.](vhrm-14-225Fig2){#f2-vhrm-14-225}

![Changes in sE-selectin, sVCAM-1, PAI-1, PDMP and adiponectin in response to treatment with PS or PE of T2DM patients.\
**Notes:** Bars show the mean±SD. 0: before M: months (after). *P*-values are for comparison with each baseline parameter (0 vs 6 and 12 months). ANOVA (PS vs PE).\
**Abbreviations:** ANOVA, analysis of variance; NS, nonsignificant; PAI-1, plasminogen activator inhibitor-1; PDMP, platelet-derived microparticle; sE-selectin, soluble E-selectin; sVCAM-1, soluble vascular cell adhesion molecule 1; PE, pitavastatin with eicosapentaenoic acid; PS, pitavastatin with sarpogrelate; T2DM, type 2 diabetes mellitus.](vhrm-14-225Fig3){#f3-vhrm-14-225}

###### 

Demographic and clinical characteristics of the T2DM patients and nondiabetic controls

                                        Controls (n=50)   T2DM (n=84)   *P*-value
  ------------------------------------- ----------------- ------------- -----------
  Men/women (no.)                       29/21             48/36         NS
  Age (years)                           62±13             74±10         \<0.05
  ABI (ratio)                           1.13±0.25         0.93±0.23     \<0.05
  BMI (kg/m^2^)                         22.1±4.1          24.5±3.9      \<0.05
  FBG (mg/dL)                           108±37            129±42        \<0.01
  HbA1c (%)                             5.3±1.9           7.2±1.2       \<0.001
  TC (mg/dL)                            221±47            212±41        NS
  HDL-C (mg/dL)                         53±16             52±14         NS
  LDL-C (mg/dL)                         129±39            126±37        NS
  Risk factor, n (%)                                                    
  Current smoking complication, n (%)   5 (10.0)          11 (13.1)     NS
  Angina pectoris                       7 (14.0)          15 (17.9)     NS
  Heart failure                         2 (4.0)           8 (9.5)       NS
  Cerebral infarction                   4 (8.0)           9 (10.7)      NS
  Hypertension medication, n (%)        11 (22.0)         24 (28.6)     NS
  ARBs                                  10 (20.0)         19 (22.6)     NS
  Ca antagonists                        5 (10.0)          14 (16.7)     NS
  Aspirin                               7 (14.0)          13 (15.5)     NS
  Sulfonylureas                         0 (0.0)           52 (61.9)     \<0.01
  α-GI                                  0 (0.0)           56 (66.7)     \<0.001
  DPP4-I                                0 (0.0)           47 (55.9)     \<0.01
  Insulin therapy                       0 (0.0)           41 (48.8)     \<0.01

**Notes:** Data are shown as mean±SD. *P*-value, T2DM patients vs nondiabetic controls.

**Abbreviations:** α-GI, α-glucosidase inhibitor; ABI, ankle brachial pressure index; ARB, angiotensin II receptor blocker; BMI, body mass index; DPP4-I, DPP4 inhibitor; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NS, not significant; T2DM, type 2 diabetes mellitus; TC, total cholesterol.

###### 

Multiple regression analysis of ABI in T2DM patients

  Analysis              Univariate   Multivariate                                                    
  --------------------- ------------ ----------------------------------------------------- --------- -----------------------------------------------------
  Age (years)           0.2247       0.08956                                                         
  Sex (men)             −0.1128      0.31257                                                         
  BMI (kg/m^2^)         −0.3395      0.00343[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.2139   0.07914
  HbA1c (%)             −0.4216      0.00287[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.2969   0.04972[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}
  UA (mg/dL)            0.0219       0.56475                                                         
  TC (mg/dL)            −0.1869      0.11239                                                         
  HDL (mg/dL)           0.2418       0.09774                                                         
  LDL (mg/dL)           −0.3125      0.00963[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.2537   0.05649
  CRP (mg/dL)           −0.4129      0.00166[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.3218   0.01024[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}
  IL-6 (pg/mL)          0.1433       0.13207                                                         
  MCP-1 (pg/mL)         −0.3127      0.01236                                               −0.2027   0.08961
  sE-selectin (ng/mL)   −0.2686      0.04423[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.1366   0.09897
  sVCAM-1 (ng/mL)       −0.2762      0.04124[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.1966   0.09567
  PDMP (U/mL)           −0.5029      0.00012[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.3984   0.01356[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}
  PAI-1 (ng/mL)         −0.5244      0.01029[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   −0.4313   0.01129[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}
  Adiponectin (μg/mL)   0.3235       0.02867[\*](#tfn3-vhrm-14-225){ref-type="table-fn"}   0.2047    0.09833

**Note:**

*P*\<0.05.

**Abbreviations:** ABI, ankle brachial pressure index; BMI, body mass index; CRP, C-reactive protein; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IL-6, interleukin-6; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant protein-1; PAI-1, plasminogen activator inhibitor-1; PDMP, platelet-derived microparticle; sE-selectin, soluble E-selectin; sVCAM-1, soluble vascular cell adhesion molecule 1; T2DM, type 2 diabetes mellitus; TC, total cholesterol; UA, uric acid.

###### 

Demographic and clinical characteristics of the PS and PE groups

                                        PS (n=38)   PE (n=38)   *P*-value
  ------------------------------------- ----------- ----------- -----------
  Men/women (no.)                       23/15       24/14       NS
  Age (years)                           72±10       76±9        NS
  ABI (ratio)                           0.94±0.19   0.93±0.21   NS
  BMI (kg/m^2^)                         24.8±5.5    24.3±3.1    NS
  FBG (mg/dL)                           123±39      127±44      NS
  HbA1c (%)                             7.3±1.3     7.1±0.9     NS
  TC (mg/dL)                            203±36      216±45      NS
  HDL-C (mg/dL)                         54±12       50±16       NS
  LDL-C (mg/dL)                         124±34      127±39      NS
  Risk factor, n (%)                                            
  Current smoking complication, n (%)   4(10.5)     6 (15.8)    NS
  Angina pectoris                       8 (21.1)    7 (18.4)    NS
  Heart failure                         4 (10.5)    3 (7.9)     NS
  Cerebral infarction                   4 (10.5)    4 (10.5)    NS
  Hypertension medication, n (%)        10 (26.3)   13 (34.2)   NS
  ARBs                                  8 (21.1)    8 (21.1)    NS
  Ca antagonists                        6(15.8)     5 (13.2)    NS
  Aspirin                               6 (15.8)    5 (13.2)    NS
  Sulfonylureas                         25 (65.8)   26 (68.4)   NS
  α-GI                                  24 (63.2)   23 (60.5)   NS
  DPP4-I                                28 (73.7)   27 (71.1)   NS
  Insulin therapy                       19 (50.0)   22 (57.9)   NS

**Notes:** Data are shown as mean±SD. *P*-value, PE vs PS.

**Abbreviations:** α-GI, α-glucosidase inhibitor; ABI, ankle brachial pressure index; ARB, angiotensin II receptor blocker; BMI, body mass index; DPP4-I, DPP4 inhibitor; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NS, not significant; PE, pitavastatin with eicosapentaenoic acid; PS, pitavastatin with sarpogrelate; TC, total cholesterol.
